Recombinant Production of Horseradish Peroxidase Conjugates with Fab
Antibodies in Pichia pastoris for Analytical
Applications by Koliasnikov, O.V. et al.
RESEARCH ARTICLES
 VOL. 3  № 3 (10)  2011  | ACTA NATURAE | 85
Recombinant Production of Horseradish 
Peroxidase Conjugates with Fab 
Antibodies in Pichia pastoris for 
Analytical Applications
O.V. Koliasnikov1,2#, V.G. Grigorenko2*#, A.M. Egorov2, S. Lange3, R.D. Schmid3
1Kolmogorov Advanced Education and Science Center, Lomonosov Moscow State University
2Department of Chemistry, Lomonosov Moscow State University
3Institute of Technical Biochemistry, University of Stuttgart 
*Е-mail: vitaly@immunotek.ru
# The authors provided equivalent contributions to the study.
Received 05.05.2011
Copyright © 2011 Park-media, Ltd. This is an open access article distributed under the Creative Commons Attribution License,which permits 
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
ABSTRACT Recombinant immunoconjugates of marker enzymes with antigens or antibodies present considerably 
more advantages than those obtained by conventional methods of chemical synthesis; i.e. they are homogeneous, 
have a strictly determined stoichiometry, and retain the functional activity of both a marker protein and an anti-
gen/antibody. Based on the pPICZαB shuttle vector, we first managed to obtain a recombinant conjugate of key 
marker enzyme horseradish peroxidase (HRP) with Fab fragments of antibodies against atrazine. The resulting 
genetic construction allows us to switch to any other antibody sequence, via the simple re-cloning of variable 
parts and an additional reporter enzyme. Conjugates were successfully produced in the Pichia pastoris methylo-
trophic yeast expression system. The target activity of the conjugates (both enzymatic and antigen-binding) has 
been demonstrated by ELISA method.
KEYWORDS horseradish peroxidase; antibodies; recombinant conjugates; Pichia pastoris expression.
ABBREVIATIONS HRP – horseradish peroxidase; ELISA – enzyme-linked immunosorbent assay; BSA – bovine 
serum albumin; PCR – polymerase chain reaction; TMB – 3,3’,5,5’-tetramethylbenzidine; ABTS – 2,2’-azinobis(3-
ethylbenzothiazoline-6-sulphonic acid).
INTRODUCTION
Enzyme immunoassays for the detection and quantita-
tive analysis of various substances are based on coupling 
of marker enzymes such as horseradish peroxidase (HRP, 
EC 1.11.1.7])  with antigens or antibodies. However, all 
major approaches used for the chemical conjugation of 
proteins and haptens result in the partial inactivation of 
the enzyme and conjugate heterogeneity, which affects 
the specificity and sensitivity of the ELISA. Genetic en-
gineering can be used to obtain recombinant conjugates 
of proteins with antigens or antibodies. Such conjugates 
present a number of advantages; firstly, they have a 
homogenous composition, secondly, they possess 1 : 1 
stoichiometry, thirdly they retain the functional activi-
ties of both the marker protein and that of the antigen/
antibody, in addition to the reproducibility and the fact 
that they are relatively simple  to produce. Recombinant 
conjugates of antibodies with alkaline phosphatase [1–3], 
luciferase [4], and peroxidase Arthromyces ramosus [5] 
were obtained earlier.
The recombinant conjugate of HRP with the ear-
lier obtained fatty-acid-binding protein (FABP) [6] 
was expressed in Escherichia coli cells and used as 
an immunotracer when performing  immunoenzyme 
assay aimed at the early diagnosis of myocardial in-
farction. 
The functional expression of the recombinant con-
jugate of HRP and antibody fragments in E. coli is as-
sociated with a number of difficulties, since there is no 
post-translational glycosylation of proteins in E. coli 
cells, resulting in low solubility and aggregation of the 
expressed/obtained protein. This problem can be solved 
by replacing the expression system. For instance, it has 
been shown that methylotrophic yeast Pichia pastoris 
is a more suitable organism/system for antibody ex-
pression than E. coli cells [7, 8].
HRP [9] and antibody fragments [10] were success-
fully expressed individually in P. pastoris cells, both 
in the single-stranded form scFv [11, 12] and in a Fab 
form [13]. Moreover, certain immunoconjugates have 86 | ACTA NATURAE |  VOL. 3  № 3 (10)  2011
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also been created using this expression system [14–16]. 
It has been demonstrated that  gene expression in the 
P. pastoris system in the secreted form considerably 
simplifies the scaling of the process for biochemical ap-
plications [17].
The recent advance in the functional expression of 
HRP and antibodies in  secreted form paves the way for 
the construction of recombinant HRP–antibody conju-
gates to be used in immunoassays. Firstly, we obtained 
recombinant conjugates of HRP and Fab-fragments of 
antibodies against atrazine, in order to study the op-
portunities provided by this approach. In these chimer-
ic proteins, the peroxidase part is combined with the 
N- and C-terminal parts of the heavy chain of an anti-
body via a short linker sequence. The universal vectors 
for the expression of conjugates of HRP and variable 
chains of Fab fragments of antibodies were obtained (a 
simple replacement of the variable part of a heavy and 
light chain of any other antibody by re-cloning at the 
PstI/BstEII and BamHI/XhoI sites, respectively) in the 
secreted form in P. pastoris cells. A functionally active 
HRP–Fab (atrazine) conjugate was obtained, possess-
ing antigen-binding properties that are similar to those 
of monoclonal antibodies, which has been attested by 
single-stage competitive immunoassay of atrazine (IC50 
~ 3 ng/ml).
EXPERIMENTAL
Reagents
The reagents were purchased from the companies Sig-
ma, Fluka, and Difco and used without further purifi-
cation. Protein electrophoresis (SDS-PAGE) was per-
formed according to the standard procedure, using a 
low molecular weight protein kit (LMW, Bio-Rad) as 
the molecular weight standards. The preparative work 
with DNA was performed using a QIA prep Spin Mini-
prep Kit and a QIAquick Gel extraction Kit (Qiagen, 
Germany). Enzymes for DNA restriction and modifica-
tion were purchased from New England Biolabs, Boe-
hringer-Mannheim, GIBCO-BRL-Life technologies, 
and MBI. Oligonucleotides for sequencing and PCR 
were purchased from ARK Scientific, MWG Biotech, 
or Interactiva (Germany).
Data processing and presentation
The gene engineering part of the study was planned 
using CloneManager software (Scientific & Educational 
Software, Cary, United States). The spatial structures 
of immunoconjugates were simulated and visualized 
on the InsightII (BioSym Inc., United States) software 
package (BioSym Inc., United States) on an SGI R4400 
operating station. The experimental data were pre-
pared for publication using software from the OpenOf-
fice.org (www.openoffice.org) and GIMP (GNU Image 
Manipulation Program) packages.
Microorganisms, media, plasmids, 
and oligonucleotides
E. coli strain DH5α was used for genetic manipulations, 
and E. coli strain BL21(DE3) pLysS (Novagen) was used 
for intermediate production of the protein. The cells 
were cultured in an LB medium (1% yeast extract, 1% 
Peptone, 0.5% NaCl) supplemented with 25 mg/l of Ze-
ocin (Invitrogen).
Preparing competent cells. E. coli cells were grown 
overnight in 50 ml of the LB medium until OD600 was 
0.4–0.6 and were isolated from the culture medium by 
centrifugation (3500 rpm, 4оС) for 10 min. The cell pre-
cipitate/pellet was re-suspended in a TSS buffer (buf- -suspended in a TSS buffer (buf- suspended in a TSS buffer (buf-
fer based on a LBS medium containing 10 g of PEG-
6000, 5 ml of DMSO, and 0.6 g of MgCl2 in 100 ml; рН 
6.5) and then kept on ice for 1 h, aliquoted (200 µl), and 
quickly frozen at –80°С.
Recombinant antibodies and their conjugates with 
HRP were expressed using  P. pastoris X33 (Invit-
rogen) and shuttle vector pPICZαB (Invitrogen) for 
cloning.
The NotI site was removed using forward and re-
verse primers (Table). A three-stage PCR was used 
(primers listed in the Table), in order to incorporate the 
HRP gene behind the gene of the heavy antibody chain 
and to remove the restriction sites BspCI, ApaI, PstI, 
BstEII, BglII, XhoI, BamHI, SacI, and PvuI. 
DNA modification and cell transformation
Manipulations with DNA included the standard pro-
cedures [18]. E. coli cells were transformed via the ad-
dition of plasmids or a ligation mixture to the unfrozen 
competent cells. P. pastoris cells were also transformed 
by plasmids preliminarily linearized at the PmeI site 
via electroporation.
P. pastoris cultivation and secretion 
of the recombinant conjugate
P. pastoris cells were cultivated in a YPD medium (1% 
yeast extract, 2% Peptone, 2% D-glucose). The target 
protein was synthesized in the glucose-free YP medi-
um, using 0.5 vol % methanol as an inducing agent. The 
YPDS medium (YPD containing 1 M sorbitol) was used 
for transformation of P. pastoris cells. The solid me-
dium contained 1.5% of Bacto Agar. The transformants 
were grown in the YPDS medium at 30°С under stir-
ring (200 rpm) until OD600 = 15 units was obtained. The 
cells were centrifuged at 3,000 g and 4°С, washed with 
YP medium, and OD600 was brought to 1. The induc-
tion was performed for 96 h by adding 0.5 vol % metha-RESEARCH ARTICLES
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nol every 24 h. The supernatant was concentrated via 
membrane ultrafiltration (Amicon, 10 kDa). 
Synthesis of bovine serum albumin 
(BSA) conjugated with atrazine
The mixture of 1 mg of atrazine derivative (4-chloro-
6-(isopropylamino)-1,3,5-triazine-2-(6-amino-caproic 
acid)) (~ 3.2 µmol), 1.7 mg of N-hydroxysuccinimide 
(~ 15 µmol), 6.6 mg of N,N’-dicyclohexylcarbodiimide 
(~ 30 µmol) in 130 µl of 1,4-dioxane was stirred for 8 h 
at room temperature. The precipitate was isolated by 
centrifuging on a desktop centrifuge (12,000 rpm, 30 s). 
The supernatant was added dropwise to the BSA so-
lution (2 mg) in 3 ml of 0.13 M NaHCO3. The reaction 
mixture was left in a dark place for 3 h. The reaction 
product was applied to a PD-10 column that was pre-
liminarily balanced with a phosphate-buffered saline 
(PBS), pH 7.5. A total of 16 fractions (0.5 ml each) were 
collected and analyzed spectrophotometrically (at 220 
and 260 nm). The fractions with the highest OD220/260 ra-
tio were combined to be used in further experiments.
Determination of activity of the 
recombinant conjugate by ELISA
ELISA was performed overnight using plates (“NUNC” 
MAXI-SORP) with the preliminarily sorbed BSA-at-
razine (1 : 100 dilution) conjugate or BSA (10 µg/ml) 
in a 10 mM carbonate buffer, pH 9.0, at 4°С. The sam-
ples of supernatant of a P. pastoris culture medium 
were successively diluted in PBS, added into the plate 
wells, and incubated at 37°С for 1 h. Then, the plate was 
washed thrice with PBS containing 0.1% of Tween-20 
(PBS-T), and 50 µl of a TMB substrate mixture was 
added (0.6 mg/ml TMB and 8 mM H2O2 in 0.1 М ace-
tate buffer, pH 5). The reaction was stopped by adding 
50 µl of 2 M H2SO4; the optical density was measured 
at 450 nm.
Competitive ELISA for determining atrazine
150 µl of the calibration sample (0.1, 1.0, 10, 20, 50, 100, 
500 ng/ml of atrazine in PBS-T) and 40 µl of a recom-
binant conjugate solution were placed into plate wells 
with the preliminarily sorbed BSA-atrazine conjugate 
and incubated at 37°С for 1 h. The plate was washed 
three times with PBS-T, and 50 µl of the TMB sub-
strate mixture was added into each well. The reaction 
was stopped by adding 50 µl of 2 M H2SO4; the optical 
density was measured at 450 nm.
RESULTS AND DISCUSSION
Recombinant conjugates are chimeric proteins com-
bining the structural components of both marker en-
zymes and an antigen/antibody. The use of  modern 
approaches has almost solved the problem of obtaining 
such recombinant enzymes as alkaline phosphatase, 
β-galactosidase, luciferase, and horseradish peroxi-
dase that are used as markers in the ELISA methods. 
However, the production of recombinant conjugates is 
an appreciably complicated task, since it remains thus 
far impossible to reliably predict the structure of the 
desired conjugate; hence,  loss of the functional activity 
of both the  marker enzyme and antigen is possible, due 
to the incorrect folding of two components.
Recombinant conjugates comprising bacterial en-
zymes (β-galactosidase and alkaline phosphatase) 
that can be easily expressed in soluble form in E. coli 
cells, as well as some other enzymes, were earlier ob-
tained. The major problem associated with the use 
of β-galactosidase and alkaline phosphatase within 
conjugates is their tetrameric and dimeric structures, 
respectively, which results in a considerable increase 
in conjugate affinity in comparison with a free anti-
body. This phenomenon is particularly undesirable 
when designing ELISA competitive schemes. Mean-
while, horseradish peroxidase, one of the marker en-
zymes that have been most widely used in ELISA, is 
expressed in E. coli cells only in the form of inclusion 
bodies, which until recently has impeded the obtain-
ing of an active enzyme.
The recent advance in the heterologous expression 
of antibody genes in the cells of methylotrophic yeast 
P. pastoris offers great opportunities for using this sys-
tem for the synthesis of the conjugates of horseradish 
conjugates with antibodies in the secreted soluble and 
functionally active forms.
Designing the expression vector to obtain a 
recombinant conjugate of HRP with a Fab 
fragment of antibodies in P. pastoris
The expression system for obtaining recombinant con-
jugates of HRP and Fab fragments of antibodies was 
elaborated on the basis of the pPICZαB vector. The ge-
netic construction was placed under the control of the 
AOX promoter containing the PmeI site for the subse-
quent linearization and recombination into the yeast 
genome. The vector also contains the signal sequence 
of α-factor, which is necessary for the directed secre-
tion of recombinant protein into the culture medium. 
Gene sh ble provides zeocin resistance of both E. coli 
and P. pastoris cell types. The possibility of introduc-
ing a hexahistidine sequence at the C-terminus of the 
recombinant protein is provided to simplify the proce-
dures of extraction and purification of the product.
We used the plasmids earlier obtained (pPIC-VCL 
and pPIC-VCH [19] containing the corresponding frag-
ments of variable regions of the light and heavy chains 
of K4E7 monoclonal antibody against atrazine [20], re-
spectively) as the starting material (Fig. 1). Both these 88 | ACTA NATURAE |  VOL. 3  № 3 (10)  2011
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vectors contained the NotI site behind the cloned gene.
To design the universal construction, we planned to 
leave only one NotI site in the vector behind the gene of 
the antibody heavy chain. PCR (the QuickChange mode 
[21]) using a special primer pair (Table) was employed 
to remove the NotI site from the pPIC-VCL plasmid. 
The vector obtained by this procedure is known as 
pPIC-VCL dNot. Then, the BglII/BamHI fragment of 
the pPIC-VCH plasmid containing the heavy-chain 
gene was cloned at the BglII site of plasmid pPIC-VCL 
dNot prior to the light chain gene. The expression vec-
tor pPIC-Fab was used. The cloning scheme is given in 
Fig. 1.
The universal pPIC-Fab gene obtained contains 
SacI/XhoI and PstI/BstEII site pairs for simple clon-
ing of the genes of the heavy and light chains, encodes 
the C-terminal hexahistidine fragment for simplify-
ing the purification of the target protein using metal 
chelate chromatography, and the NotI site for cloning 
the marker protein (such as HRP, green fluorescent 
protein (EGFP), luciferase, etc.) at the C-terminus of 
the heavy chain of the antibody.
A vector for the expression of the recombinant con-
jugate of peroxidase with Fab fragments of antibod-
ies was designed simultaneously. For the simplicity of 
cloning, restriction sites PstI, BstEII, BglII, XhoI, SacI, 
PvuI, ApaI, BamHI and BspCI were removed using the 
primers listed earlier (Table) from the initial HRP gene 
[22] that was preliminarily cloned in the corresponding 
pPIC vector. Either before the HRP gene or behind it 
the fragments of antibody genes were simultaneously 
cloned. Thus, three-stage PCR was used to obtain two 
genetic constructions in which the HRP gene was linked 
with the sequence encoding the N-terminal region of 
the variable part of the heavy Fab chain or the C-ter-
minal region of the constant part of the heavy chain 
via a short linker sequence (Gly4Ser)3 (Fig. 2). It should 
be mentioned that in order to avoid the formation of 
pPIC-VCL pPIC-VCH
Quick 
Change
BglII/BamHI
BglII
ColE1 5AOX1
alpha
SfuI
VL
CL
SacI
PstI
XhoI
EcoRI
NotI BamHI
sh ble
BglII
ColE1 5AOX1
PmeI
alpha
SfuI
PstI VH
CH his-tag BstEII
EcoRI
NotI BamHI
sh ble
pPIC-VCL dNot BglII
ColE1 5AOX1
alpha
SfuI
VL
CL
SacI
PstI
XhoI
XhoI EcoRI
PvuI BamHI
BamHI sh ble
pPIC-Fab
BglII BglII
ColE1 5AOX1
5AOX1
PmeI
alpha
SfuI
PstI
VH
CH
his-tag
BstEII
EcoRI
NotI
PvuI
sh ble
SacI
alpha VL
CL
SfuI
PstI
EcoRI
PvuI
Fig. 1. Cloning scheme 
for construction of pPIC 
Fab plasmid.RESEARCH ARTICLES
 VOL. 3  № 3 (10)  2011  | ACTA NATURAE | 89
Forward (F) and reversed (R) primers used for generation of genetic constructs with PCR. The introduced mutations are 
indicated in bold and underlined in primer sequences
Target gene Restriction site destroyed Primer sequence*
HRP NotI R ‵鈭䍇䅔䍇䅇䍃⁇䍇 AT䝇䍃䜠䍃䅇䌭㎒
HRP NotI F ‵鈭䝃呇䝃䝇䍃 AT䍇䍇䝃呃⁇䅔䍇ⴳ
Fab VCH R ‵鈭䅇䝃䅃䅇䍔⁁呁䝇呁䍇ⴳ
Fab VCH F ‵鈭呇䅇䅁䍃呃⁃䅃䍇䍃䝃䄠䝔䍇䍇䍇䝔⁁䍇ⴳ
HRP R ‵鈭䝃䝇䍇䝔䝇⁁䝇呔䍔䍁䜠呔䅁䍇䍃䝁⁃呔呃呁䍇ⴳ
HRP PstI, BspCI R ‵鈭䝁 C䍇䍁呇䄠䅇䝃呇 T䝔⁃䜭㎒
HRP PstI, BspCI F ‵鈭䅃 A䝃䅇䍃吠呃䅔䝃 G呃⁇ⴳ
HRP BstEII, ApaI R ‵鈭䅃 T䍔䅇䍃䜠䝃䝇 T䍃䍔䌭㎒
HRP BstEII, ApaI F ‵鈭䝇 A䍃䝃䍇䜠䍔䅇 A䝔䝁䌭㎒
HRP XhoI R ‵鈭䝁䅃䍇 T呃䜠䅇呇䅔䍔䅇ⴳ
HRP XhoI F ‵鈭䅇䅔䍁䍔䍇⁁ A䍇䝔呃䅇ⴳ
HRP SacI R ‵鈭䝁呃䅇䝁䝃⁔ G呔䍔䍁呃ⴳ
HRP SacI F ‵鈭䅁 C䅇䍔䍃吠䝁呃䅇䅔呇ⴳ
Fab VCL NotI R ‵鈭䅔䍇䝔䅃䍔⁃䝁呃䝁䝃䌠䝃 AT䝇ⴳ
Fab VCL NotI F ‵鈭呇䅁䝔䝇呁⁃䝇䍇䅔䝃ⴳ
* The nucleotide sequence regions that were changed are highlighted.
5AOX1
5AOX1 5AOX1
5AOX1
'5AOX1
ColE1 ColE1
alpha
alpha
alpha alpha
alpha
HRP
HRP HRP
HRP
sh ble sh ble VH
VH
'VH VH
CH
CH
CH CH'
his-tag
his-tag
his-tag VL VL
CL CL
BglII BglII
PmeI PmeI
PmeI
SfuI
SfuI
SfuI
BstEII
BstEII
PstI
PstI
PstI
PstI NotI NotI
XhoI XhoI
SacI SacI SfuI SfuI
NotI
NotI
PvuI
BstEII BstEII
pPIC-Ab-HRP pPIC-HRP-Ab
Fig. 2. Gen-
eral versatile 
expression 
vectors for 
recombinant 
conjugates of 
HRP with Fab 
antibody frag-
ments pro-
duction. The 
spatial models 
of recombinant 
conjugates 
of Fab-HRP 
and HRP-Fab 
are shown in 
the left and 
right panels, 
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PBS-T
Recombinant  
conjugate  
Fab-HRP
Unbound 
atrazine
Chemical conju-
gate BSA–atrazine
TMB
 H2O2
TMB
 H2O2
Measure-
ment of А450
Measure-
ment of А450
Fig. 3. ELISA scheme for atrazine determination.
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Fig. 4. Titration of recombinant conjugates: 1 – Fab-
HRP (clone 1.1); 2 – Fab-HRP (clone 1.2); 3 – HRP-Fab 
(clone 8).
nonfunctional dimers of the light chain, genetic con-
structions were cloned in the pPIC-Fab vector at the 
sites PmeI/BstEII and BstEII/NotI, respectively; the 
heavy chain was selected for the cloning of the marker 
protein gene. The mutual arrangement of genes in plas-
mids pPIC-Ab-HRP and pPIC-HRP-Ab was confirmed 
by restriction analysis and sequencing.
Expression and purification of recombinant 
conjugates Fab-HRP and HRP-Fab
P. pastoris X33 cells (Invitrogen) were transformed via 
the plasmid vectors pPIC-Ab-HRP and pPIC-HRP-Ab 
using electroporation with an efficiency of approxi-
mately 100 clones per 10 µg of plasmid DNA. The ex-
pression of the target protein was tracked by increasing 
the peroxidase activity in the supernatant of the culture 
medium, reaching a plateau on day 5 of cultivation. Ten 
clones were analyzed with each construction. The HRP 
activity with respect to the TMB substrate was detected 
only in three clones out of 20: two clones (1.1, 1.2) cor-
responding to pPIC-Ab-HRP and one clone (8) corre-
sponding to pPIC-HRP-Ab. These clones were selected 
for further consideration.
As shown by SDS-PAGE electrophoresis (the data 
are not provided), the blurred bands located below the 
band at 100 kDa correspond to the recombinant con-
jugates HRP-VCH and VCH-HRP. This blurriness of 
the bands is accounted for by the microheterogeneity 
of conjugates, conditioned by excessive glycosylation 
that is typical for P. pastoris; correlating with our data 
and the data published on the expression of the HRP 
gene [9]. A considerably greater excess (by a factor of 
3–4) of light-chain molecules was observed (the band at 
25 kDa) in comparison with that found during the ex-
pression of the Fab fragment [19]. Unexpectedly, it oc-
curred that the recombinant conjugated manifested no 
enzymatic activity toward another peroxidase substrate, 
ABTS, as opposed to TMB. It is well known that the site 
of binding with ABTS is located in the hydrophobic re-
gion on the HRP surface, in the so-called “Phe patch” 
zone [25]. This zone is noticeably distant from the active 
site of HRP, and it can be assumed that the substrate 
binding to it is complicated due to steric reasons – as 
a result of excessive glycosylation or the presence of a 
Fab fragment of antibody. The first hypothesis is more 
probable, since the same effect is observed under both 
positions of the heavy chain of the antibody with respect 
to HRP. Moreover, a similar effect was earlier observed 
upon expression of the HRP gene in P. pastoris (the data 
have not been published).
The total yield of recombinant conjugates was ap-
proximately 3–10 mg per 1 l of the P. pastoris culture 
supernatant. A relatively low yield of secreted con-
jugates correlates with the yield upon expression of 
the HRP gene only. We believe that one of the factors 
that have a negative effect on the yield of the secreted 
product is the excessive glycosylation of the peroxidase 
component of the conjugate, which is typical of P. pas-
toris cells. In order to verify this hypothesis, it may be 
reasonable to remove all N-glycosylation sites in HRP 
or replace HRP with another reporter protein, such as 
EGFP.
Characterization of recombinant 
conjugates by ELISA
In order to confirm the antigen-binding activity of re-
combinant conjugates, we selected the scheme of indi-
rect competitive single-stage ELISA (Fig. 3) carried out 
on the wells with an immobilized atrazine–BSA conju-
gate. The binding of recombinant conjugates to atrazine 
was preliminarily studied (Fig. 4). The data obtained 
attest to the presence of both catalytic and antibody RESEARCH ARTICLES
 VOL. 3  № 3 (10)  2011  | ACTA NATURAE | 91
A
b
s
o
r
b
a
n
c
e
,
 
А
4
5
0
 
Atrazine concentration, ng/ml
0.01  0.1  1  10
1.6
1.4
1.2
1.0
0.8
0.6
0.4
0.2
Fig. 5. Calibration curve for atrazine determination in com-
petitive ELISA with recombinant conjugate of Fab-HRP 
(clone 1.1).
activity in all three clones. However, the low activity of 
the HRP-Fab sample (clone 8) in comparison with the 
C-terminal conjugate Fab-HRP (clones 1.1 and 1.2) may 
attest to the fact that the mutual spatial arrangement 
of two components of the chimeric protein in this case 
results in a decrease in the catalytic activity of peroxi-
dase. The samples of recombinant conjugates Fab–HRP 
(clones 1.1 and 1.2) have similar characteristics, and 
specimen 1.1 was used for further ELISA determina-
tion of atrazine. The typical calibration diagram (Fig. 5) 
allows one to determine the atrazine concentration over 
a wide range, from 0.1 to 50 ng/ml; the variation coef-
ficient being no higher than 8%. IC50 is equal to 3 ng/ml, 
which agrees well with the results of atrazine determi-
nation by a two-stage ELISA procedure using recom-
binant Fab fragments of the same antibody K411B [19] 
and with the data on the single-chain mini-antibody 
(scFv) obtained earlier in E. coli [24]. Meanwhile, in the 
initial monoclonal antibody, the IC50 value was equal to 
0.2 ng/ml [19]. As is evident in the majority of similar 
cases, the fact that the IC50 value differs from that of 
recombinant antibodies is in all likelihood connected 
with the bivalence of the initial monoclonal antibody.
Thus, the recombinant conjugates of peroxidase with 
Fab fragments of antibody against atrazine obtained in 
the present study possess functional activity and can be 
used to determine atrazine via ELISA.
CONCLUSIONS
The possibility of using a recombinant, functionally ac-
tive HRP (as a marker enzyme) conjugated with Fab 
fragments of the antibody against atrazine was  shown 
for the first time. In the present study,  recombinant 
conjugates were obtained in which the Fab fragment of 
an antibody is bound both to the N- and the C- termi-
nuses of the marker enzyme. Both these variants mani-
fest immunological and catalytic activity.
The functional secretion of recombinant conjugates 
of HRP with Fab fragments of antibodies offers op-
portunities for broad application in ELISA. The results 
obtained will be used to design highly sensitive immu-
nobiosensors of a new generation, based on the recom-
binant DNA technology. 
The study was partially supported by the German 
Federal Ministry of Science and Technology (BMBF, 
grant № 0311574).
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